{"id":745349,"date":"2016-06-29T06:00:00","date_gmt":"2016-06-29T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/"},"modified":"2025-11-07T01:25:44","modified_gmt":"2025-11-07T06:25:44","slug":"merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/","title":{"rendered":"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Collaboration Combines Merck\u2019s Leadership in Immuno-Oncology with        Moderna\u2019s Pioneering mRNA Vaccine Technology and Rapid Cycle Time,        Small-Batch GMP Manufacturing Capabilities     <\/p>\n<p>KENILWORTH, N.J. &amp; CAMBRIDGE, Mass.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Moderna Therapeutics today announced a strategic collaboration and<br \/>\n      license agreement to develop and commercialize novel messenger RNA<br \/>\n      (mRNA)-based personalized cancer vaccines. The collaboration will<br \/>\n      combine Merck\u2019s established leadership in immuno-oncology with Moderna\u2019s<br \/>\n      pioneering mRNA vaccine technology and GMP manufacturing capabilities to<br \/>\n      advance individually tailored cancer vaccines for patients across a<br \/>\n      spectrum of cancers.\n    <\/p>\n<p>\n      Moderna and Merck will develop personalized cancer vaccines that utilize<br \/>\n      Moderna\u2019s mRNA vaccine technology to encode a patient\u2019s specific<br \/>\n      neoantigens, unique mutations present in that specific patient\u2019s tumor.<br \/>\n      When injected into a patient, the vaccine will be designed to elicit a<br \/>\n      specific immune response that will recognize and destroy cancer cells.<br \/>\n      The companies believe that the mRNA-based personalized cancer vaccines\u2019<br \/>\n      ability to specifically activate an individual patient\u2019s immune system<br \/>\n      has the potential to be synergistic with checkpoint inhibitor therapies,<br \/>\n      including Merck\u2019s anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab). In addition, Moderna has developed a rapid cycle time,<br \/>\n      small-batch manufacturing technique that will uniquely allow the company<br \/>\n      to supply vaccines tailored to individual patients within weeks.\n    <\/p>\n<p>\n      Under the terms of the agreement, Merck will make an upfront cash<br \/>\n      payment to Moderna of $200 million, which Moderna will use to lead all<br \/>\n      research and development efforts through proof of concept. The<br \/>\n      development program will entail multiple studies in several types of<br \/>\n      cancer and include the evaluation of mRNA-based personalized cancer<br \/>\n      vaccines in combination with Merck\u2019s KEYTRUDA\u00ae (pembrolizumab). Moderna<br \/>\n      will also utilize the upfront payment to fund a portion of the build-out<br \/>\n      of a GMP manufacturing facility in suburban Boston for the purpose of<br \/>\n      personalized cancer vaccine manufacturing.\n    <\/p>\n<p>\n      Following human proof of concept studies, Merck has the right to elect<br \/>\n      to make an additional undisclosed payment to Moderna. If exercised, the<br \/>\n      two companies will then equally share cost and profits under a worldwide<br \/>\n      collaboration for the development of personalized cancer vaccines.<br \/>\n      Moderna will have the right to elect to co-promote the personalized<br \/>\n      cancer vaccines in the U.S. The agreement entails exclusivity around<br \/>\n      combinations with KEYTRUDA. Moderna and Merck will each have the ability<br \/>\n      to combine mRNA-based personalized cancer vaccines with other (non-PD-1)<br \/>\n      agents.\n    <\/p>\n<p>\n      \u201cCombining immunotherapy with vaccine technology may be a new path<br \/>\n      toward improving outcomes for patients,\u201d said Dr. Roger Perlmutter,<br \/>\n      president, Merck Research Laboratories. \u201cWhile the area of personalized<br \/>\n      cancer vaccine research has faced challenges in the past, there have<br \/>\n      been many recent advances, and we believe that working with Moderna to<br \/>\n      combine an immuno-oncology approach, using KEYTRUDA, with<br \/>\n      mRNA-based&nbsp;personalized cancer vaccines may have the potential to<br \/>\n      transform the treatment of cancer.\u201d\n    <\/p>\n<p>\n      \u201cOur team has made significant progress since beginning our work in<br \/>\n      personalized cancer vaccines just last year. Through this collaboration<br \/>\n      with Merck, we are now well-positioned to accelerate research and<br \/>\n      development with a goal of entering the clinic in 2017, as well as to<br \/>\n      apply our unique GMP manufacturing capabilities to support the rapid<br \/>\n      production of these highly individualized vaccines,\u201d said<br \/>\n      St\u00e9phane&nbsp;Bancel, chief executive officer of Moderna. \u201cWe value our<br \/>\n      continued collaboration with Merck, and we look forward to working<br \/>\n      together to harness the potential of personalized cancer vaccines and<br \/>\n      immuno-oncology to bring a new treatment paradigm to patients.\u201d\n    <\/p>\n<p>\n      Merck and Moderna have an existing collaboration and license agreement<br \/>\n      focused on the discovery and development of mRNA-based infectious<br \/>\n      disease vaccines and passive immunity treatments. Moderna is also<br \/>\n      advancing its own pipeline of infectious disease vaccine candidates and<br \/>\n      currently has two phase 1 studies underway in Europe and the U.S.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>&nbsp;(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA\u00ae (pembrolizumab). Pneumonitis occurred in 32 (2.0%)<br \/>\n      of 1567 patients with melanoma, including Grade 1 (0.8%), 2 (0.8%), and<br \/>\n      3 (0.4%) pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%)<br \/>\n      pneumonitis and more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3;<br \/>\n      permanently discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Hepatitis occurred in 16 (1%) of 1567 patients with melanoma, including<br \/>\n      Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1567 patients with melanoma, including Grade 3<br \/>\n      (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. Thyroid<br \/>\n      disorders can occur at any time during treatment. Monitor patients for<br \/>\n      changes in thyroid function (at the start of treatment, periodically<br \/>\n      during treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Nephritis occurred in 7 (0.4%) of 1567 patients with melanoma including,<br \/>\n      Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA (pembrolizumab) for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA \u00ae (pembrolizumab)<br \/>\n      and administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 6, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n      555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      In Trial 2, KEYTRUDA was discontinued due to adverse reactions in 12% of<br \/>\n      357 patients with advanced melanoma; the most common (\u22651%) were general<br \/>\n      physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%).<br \/>\n      The most common adverse reactions with KEYTRUDA vs chemotherapy were<br \/>\n      fatigue (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported at least<br \/>\n      2% of patients were pleural effusion, pneumonia, dyspnea, pulmonary<br \/>\n      embolism, and pneumonitis. The most common adverse reactions (reported<br \/>\n      in at least 20% of patients) were fatigue (44%), cough (29%), decreased<br \/>\n      appetite (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 300 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=7c48890458130082e07fa2580e8ef349\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=cad0dfc22e866ce392f63e842f9d2893\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=aba5f11701f4e342e49e4e0396590f8d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=d26a4c5e90fd3f54e2228232626c5fce\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=070fd9c90fe0a2d802acf82db450e71d\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=594d112c215ba23ca2be3e1d0d3471d1\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>About Moderna Therapeutics<\/b>\n    <\/p>\n<p>\n      Moderna is a clinical stage pioneer of <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Fmrna-expression-platform&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=messenger+RNA+Therapeutics%E2%84%A2&amp;index=7&amp;md5=109bdc71145a20fd3c0ec75c721c90e4\" rel=\"nofollow\">messenger<br \/>\n      RNA Therapeutics\u2122<\/a>, an entirely new in vivo drug technology that<br \/>\n      produces human proteins, antibodies and entirely novel protein<br \/>\n      constructs inside patient cells, which are in turn secreted or active<br \/>\n      intracellularly. This breakthrough platform addresses currently<br \/>\n      undruggable targets and offers a potentially superior alternative to<br \/>\n      existing drug modalities for a wide range of diseases and conditions.<br \/>\n      Moderna is developing and plans to commercialize its innovative mRNA<br \/>\n      drugs through its own ventures and its strategic relationships with<br \/>\n      established pharmaceutical and biotech companies. Its current ventures<br \/>\n      are: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Four-business-model%2Fventures%2Fonkaido&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Onkaido&amp;index=8&amp;md5=673904345b4c21dca32e521d97044be4\" rel=\"nofollow\">Onkaido<\/a>,<br \/>\n      focused on oncology, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Four-business-model%2Fventures%2Fvalera&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Valera&amp;index=9&amp;md5=c5c986143e7992ec7b5e05b128eed947\" rel=\"nofollow\">Valera<\/a>,<br \/>\n      focused on infectious diseases, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Four-business-model%2Fventures%2Felpidera&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Elpidera&amp;index=10&amp;md5=8907f9e1b6186eb560a5cc405041e636\" rel=\"nofollow\">Elpidera<\/a>,<br \/>\n      focused on rare diseases, and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Four-business-model%2Fventures%2Fcaperna-llc&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Caperna&amp;index=11&amp;md5=d442dfd21d0290f5e1787d3d3641b1f6\" rel=\"nofollow\">Caperna<\/a>,<br \/>\n      focused on personalized cancer vaccines. Cambridge-based Moderna is<br \/>\n      privately held and currently has strategic agreements with <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Fnews-events%2Fpress-releases%2Fastrazeneca-and-moderna-therapeutics-announce-exclusive-agreement-develop&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=AstraZeneca&amp;index=12&amp;md5=b562c292f4b32544e93bb7cbaf47d069\" rel=\"nofollow\">AstraZeneca<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Fnews-events%2Fpress-releases%2Falexion-pharmaceuticals-and-moderna-therapeutics-announce-exclusive&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Alexion+Pharmaceuticals&amp;index=13&amp;md5=9fa29ef7d18d708829fbd502254329c7\" rel=\"nofollow\">Alexion<br \/>\n      Pharmaceuticals<\/a> and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2Fnews-events%2Fpress-releases%2Fmoderna-announces-license-and-collaboration-agreement-with-merck&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=Merck&amp;index=14&amp;md5=af1b639168c86712620d4161d2b35c23\" rel=\"nofollow\">Merck<\/a>.<br \/>\n      To learn more, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=www.modernatx.com&amp;index=15&amp;md5=945e08367fb4557d22eba09bd00b4360\" rel=\"nofollow\">www.modernatx.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=16&amp;md5=2e89ab8a2b217b420b305775d61456b1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=17&amp;md5=fcb09a8e0bd76f257118142c38e4c31c\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51371660&amp;newsitemid=20160629005446&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=18&amp;md5=b7d9ca5ab939c4d77cd0fe4a0dbce314\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160629005446r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck <br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879<br \/>or<br \/> Moderna <br \/>Media:<br \/>Liz        Melone, 617-256-6622<br \/>or<br \/>Investors:<br \/>Maren Winnick,        617-674-5297     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck\u2019s established leadership in immuno-oncology with Moderna\u2019s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers. Moderna and Merck will develop personalized cancer vaccines that utilize Moderna\u2019s mRNA vaccine technology to encode a patient\u2019s specific neoantigens, unique mutations present in that specific patient\u2019s tumor. When injected into a patient, the vaccine will be designed to elicit a specific immune response that will recognize and destroy cancer cells. The companies believe that the mRNA-based personalized cancer vaccines\u2019 ability to specifically activate an individual patient\u2019s immune<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745349","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck\u2019s established leadership in immuno-oncology with Moderna\u2019s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers. Moderna and Merck will develop personalized cancer vaccines that utilize Moderna\u2019s mRNA vaccine technology to encode a patient\u2019s specific neoantigens, unique mutations present in that specific patient\u2019s tumor. When injected into a patient, the vaccine will be designed to elicit a specific immune response that will recognize and destroy cancer cells. The companies believe that the mRNA-based personalized cancer vaccines\u2019 ability to specifically activate an individual patient\u2019s immune\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\\\/\",\"name\":\"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-06-29T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck\u2019s established leadership in immuno-oncology with Moderna\u2019s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers. Moderna and Merck will develop personalized cancer vaccines that utilize Moderna\u2019s mRNA vaccine technology to encode a patient\u2019s specific neoantigens, unique mutations present in that specific patient\u2019s tumor. When injected into a patient, the vaccine will be designed to elicit a specific immune response that will recognize and destroy cancer cells. The companies believe that the mRNA-based personalized cancer vaccines\u2019 ability to specifically activate an individual patient\u2019s immune","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:44+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/","name":"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-06-29T06:00:00+00:00","dateModified":"2025-11-07T06:25:44+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Multiple Types of Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b4c81e05-8394-4866-8e95-bb63ef251cda","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/06\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/06\/1\/Moderna_Logo.jpg","size":"46983","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Moderna-Announce-Strategic-Collaboration-to-Advance-Novel-mRNA-Based-Personalized-Cancer-Vaccines-with-KEYTRUDA-pembrolizum-K9J8W.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745349\/revisions"}],"predecessor-version":[{"id":3674754,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745349\/revisions\/3674754"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745349"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}